

Special Issue

Cancer-Induced Immunosuppressive Mechanism

Message from the Guest Editor

Dear colleagues, Low response rates and the frequent lack of long-term benefits in patients have called scientists' and clinicians' attention to the complex crosstalk between tumor and immune cells. Indeed, it has become increasingly clear that tumors use several mechanisms to suppress anti-tumor immunity, within the tumor microenvironment as well as systemically, and that this escape of tumors from the host immune system may be a major barrier to successful immunotherapy. Therefore, the identification and understanding of the various tumor-induced immunosuppressive mechanisms is essential for the future development of effective immunotherapies and may provide new therapeutic targets. This Special Issue will bring together the newest original research, short communications, and review articles on tumor-induced immune suppression, including such topics as immunosuppressive factors, recruitment of suppressive or regulatory cells, immune cell reprogramming, tumor microenvironment editing, immune checkpoints, the role of EVs in cancer/immune cell cross-talk, metabolics, and tumor-derived EVs.


Guest Editor

Dr. Malgorzata Czystowska-Kuzmicz

Chair and Department of Biochemistry, Medical University of Warsaw,
00-927 Warszawa, Poland

Deadline for manuscript submissions

closed (25 March 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/58012

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).